Key Points Telix administered the first U.S. commercial doses of Pixclara at medical centers in Indianapolis and Cleveland. Pixclara is the only FDA-approved radiopharmaceutical imaging…
September 18, 2026
Hong Kong Patent Extends bioAffinity’s CyPath Lung Protection in Asia
bioAffinity Technologies (NASDAQ: BIAF) has received a patent in Hong Kong covering CyPath Lung, its noninvasive lung cancer test. The grant follows a Chinese patent…
Key Points Pulse Biosciences completed enrollment of 100 patients in its PRECISE-BTN clinical study. The study is evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for…
September 14, 2026
FDA Approves Telix’s Pixclara for Glioma Brain Cancer Imaging
Key Points The FDA approved Telix Pharmaceuticals’ Pixclara® for PET imaging in patients with glioma, a form of brain cancer. Pixclara is the first FDA-approved…
Key Points AvMEDICAL will market CyPath Lung through its national sales team and established federal procurement network. The agreement targets VA medical centers and other…
bioAffinity Technologies (Nasdaq: BIAF) is highlighting a new clinical framework that explains where CyPath® Lung may fit in the evaluation of pulmonary nodules and ongoing…
Tempus AI (NASDAQ: TEM) just added another rare‑disease data asset to its oncology flywheel, and the stock inched higher on the news. Shares rose about…
Prelude Corporation (PreludeDx), a precision‑diagnostics company focused on early‑stage breast cancer, received FDA Breakthrough Device designation for its AidaBREAST test. This is the company’s second Breakthrough Device;…